Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-label Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

Next Previous
X
Search
Trial Profile

A Phase 2 Open-label Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Danicopan (Primary) ; Eculizumab (Primary) ; Benzathine benzylpenicillin/benzylpenicillin/procaine-benzylpenicillin; Hib vaccine conjugate; Meningococcal vaccine group B OMV Novartis; Meningococcal vaccine groups A C Y W-135 conjugate; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Proof of concept; Therapeutic Use
  • Acronyms PNH
  • Sponsors Achillion Pharmaceuticals; Alexion AstraZeneca Rare Disease

    • Most Recent Events

    • 01 Feb 2023 Status changed from active, no longer recruiting to completed.
    • 15 Aug 2022 Planned End Date changed from 22 Jul 2022 to 31 Jul 2023.
    • 18 Feb 2022 Planned End Date changed from 28 Feb 2022 to 22 Jul 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top